《中国药物性肝损伤诊治指南2023年版》解读
Interpretation of the 2023 Chinese Guidelines for the diagnosis and treatment of drug-induced liver injury
布橦 1王琦1
作者信息
- 1. 首都医科大学附属北京地坛医院 肝病中心,北京 100011
- 折叠
摘要
药物性肝损伤(DILI)是一种重要的药物不良反应,严重威胁患者的生命健康.近年来,DILI领域的研究取得了显著进展,提出了许多新观点和新证据.2023年,中华医学会肝病学分会药物性肝病学组更新并发布了《中国药物性肝损伤诊治指南2023年版》.新版指南基于最新证据,对DILI的定义、临床分型、诊断及鉴别诊断、治疗和预防、预后及随访等重要临床问题提出了指导性建议.本文旨在通过对该指南的重点内容进行解读,帮助临床工作者更全面深刻地理解指南,并用于指导临床实践.
Abstract
Drug-induced liver injury(DILI)is a significant adverse drug reaction that severely threatens patients'lives and health.In recent years,there has been remarkable progress in the field of DILI research,with the introduction of many perspectives and evidence.In 2023,the Hepatology Branch of the Chinese Medical Association and the Drug-Induced Liver Disease Group updated and released the"2023 Chinese Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury."The new guidelines,based on the latest evidence,provide guiding recommendations on important clinical issues such as definition,clinical staging,diagnosis and differential diagnosis,treatment and prevention,prognosis,and follow-up of DILI.This article aims to help clinical practitioners understand the guidelines more comprehensively and deeply by interpreting the key content and applying it to guide clinical practice.
关键词
药物性肝损伤/指南/诊断/治疗Key words
drug-induced liver injury/guidelines/diagnosis/treatment引用本文复制引用
出版年
2024
NETL
NSTL
万方数据